Publicaciones en colaboración con investigadores/as de Aarhus University Hospital (41)

2024

  1. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx (Nature, (2023), 616, 7957, (525-533), 10.1038/s41586-023-05783-5)

    Nature

  2. Clinical practice in European centres treating paediatric posterior fossa tumours with pencil beam scanning proton therapy

    Radiotherapy and Oncology, Vol. 198

  3. EUSOMA quality indicators for non-metastatic breast cancer: An update

    European Journal of Cancer, Vol. 198

  4. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics

  5. Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling

    Nature Communications, Vol. 15, Núm. 1

  6. Representation of genomic intratumor heterogeneity in multi-region non-small cell lung cancer patient-derived xenograft models

    Nature Communications , Vol. 15, Núm. 1

  7. The artificial intelligence-based model ANORAK improves histopathological grading of lung adenocarcinoma

    Nature Cancer, Vol. 5, Núm. 2, pp. 347-363

2023

  1. Antibodies against endogenous retroviruses promote lung cancer immunotherapy

    Nature, Vol. 616, Núm. 7957, pp. 563-573

  2. Body composition and lung cancer-associated cachexia in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 846-858

  3. EBCC-13 manifesto: Balancing pros and cons for contralateral prophylactic mastectomy

    European Journal of Cancer, Vol. 181, pp. 79-91

  4. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Vol. 183, pp. 109589

  5. ESGO/ESTRO quality indicators for radiation therapy of cervical cancer

    International Journal of Gynecological Cancer, Vol. 33, Núm. 6, pp. 862-875

  6. ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer – Update 2023

    Radiotherapy and Oncology, Vol. 184

  7. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

    Nature Medicine, Vol. 29, Núm. 4, pp. 833-845

  8. Genomic–transcriptomic evolution in lung cancer and metastasis

    Nature, Vol. 616, Núm. 7957, pp. 543-552

  9. Lung adenocarcinoma promotion by air pollutants

    Nature, Vol. 616, Núm. 7955, pp. 159-167

  10. Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi

    Molecular Therapy Nucleic Acids, Vol. 34

  11. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

  12. The Lucerne Toolbox 2 to optimise axillary management for early breast cancer: a multidisciplinary expert consensus

    eClinicalMedicine, Vol. 61

  13. The evolution of lung cancer and impact of subclonal selection in TRACERx

    Nature, Vol. 616, Núm. 7957, pp. 525-533